The Indore-based pharmaceutical company specialises in corticosteroid and steroidal-hormone APIs.
| Photo Credit:
iStockphoto
Price Band: ₹ 938 to ₹ 988 a share ˘of face value of ₹ 2 eachIssue period: The Bid /Offer opens August 24-27 2026. Lot size: Bids can be made for a minimum of 15 Equity Shares and in multiples of 15 Equity Shares thereafter.Offer size: Total size: Rs 1,757 crore: A fresh issue of ₹150 crore and offer for sale of up to ₹1,607 crore. Promoter Satwani Holdings LLP and investors Rosewood Investments and India Business Excellence Fund III are selling shares through OFS.IPO quota: 50% for QIBs, 15 per cent for NIIs and 35 per cent for retail investors. Discount Of ₹ 90 a shareis being offered to Eligible Employees Bidding in the Employee Reservation Portion.Anchor investors: Raised Rs 526 crore from anchor investors including HDFC Mutual Fund, ICICI Prudential Mutual Fund, Motilal Oswal Mutual Fund, Citigroup Global Markets Mauritius, BNP Paribas Financial Markets, Bajaj Life Insurance, Tata AIA Life Insurance, Mirae Asset, Tata Mutual Fund and Edelweiss Mutual Fund.Exchanges: BSE and NSEBRLMs: JM Financial Ltd, Avendus Capital Pvt Ltd, Motilal Oswal Investment Advisors Ltd and Nomura Financial Advisory and Securities (India) Pvt LtdUsage of fresh issue: Proceeds of the fresh issue will be used for debt payment and general corporate purposes.About the company: Symbiotec Pharmalab is an Indore-based research and development-driven pharmaceutical and biotechnology company with capabilities across three platforms – organic chemistry, biotechnology and complex injectables. It’s a global leader in corticosteroid and steroidal-hormone active pharmaceutical ingredients (APIs).Brokers’ views:SBI Securities: Symbiotec Pharmalab is a pharmaceutical and biotechnology company with capabilities across organic chemistry, biotechnology and complex injectables. The company carries a global leadership position in corticosteroid and steroidal-hormone APIs in volume terms. Historically, the company has recorded Revenue/EBITDA/Adj. PAT CAGR of 10.2%/17.8%/7.8% respectively over the FY24-FY26 period. At the upper price band of Rs 988, the issue is valued at FY26 P/E multiple of 54.6x based on post-issue capital. Upon comparing with its peers, the issue appears to be reasonably valued. We recommend investors to SUBSCRIBE to the issue at the cut-off price.Published on August 24, 2026
